Corcept Therapeutics (CORT) Misses Q4 EPS by 5c ; Offers Guidance
Tweet
Share
E-mailGet Alerts CORT Hot Sheet
Price: $111.62 --0%
Revenue Growth %: +54.6%
Financial Fact:
Research and development: 7.05M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: +54.6%
Financial Fact:
Research and development: 7.05M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Corcept Therapeutics (NASDAQ: CORT) reported Q4 EPS of $0.20, $0.05 worse than the analyst estimate of $0.25. Revenue for the quarter came in at $202.12 million versus the consensus estimate of $249.52 million.
GUIDANCE:
Corcept Therapeutics sees FY2026 revenue of $0.9-1 billion, versus the consensus of $0.96 billion.
For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Verizon and Corning reach multi-billion fiber supply deal
- Piper Sandler Reiterates Overweight Rating on Tyra Biosciences (TYRA) Ahead of Dabo IR NMIBC Readout
- HSBC Raises S&P500 Target to 8,100
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
